CHANDLER, Ariz., Feb. 19, 2013 /PRNewswire/ -- Vomaris Innovations, Inc., a leading edge regenerative medicine company focusing on wound care with bioelectric technology, is pleased to announce the initiation of a new study with Walter Reed National Military Medical Center.
The objective of the study, funded by the Henry M. Jackson Foundation for the Advancement of Military Medicine, is the assessment of the clinical efficacy of a bioelectric dressing (Procellera®) in conjunction with standard-of-care on the healing rate of chronic soft tissue wounds compared with standard-of-care alone.
In this 50-subject study, the primary endpoint for efficacy will be the rate of healing (healing trajectory) in the treatment group compared to that of the control group, during the 12-week treatment study period. It is hypothesized that a bioelectric dressing will reduce wound healing time when compared to SOC treatment, thereby accelerating wound healing trajectory.
" Walter Reed's selection of Procellera® for a study of this significance is an exceptionally positive indicator for the future of Vomaris, and our proprietary bioelectric technology," said Michael P. Nagel, Vomaris President and CEO."Field experience along with our clinical studies continues to show that Procellera® has the potential to transform wound care as we know it today," Nagel said. "Proving Procellera's impact in a study associated with the Combat Wound Initiative will provide another layer of critical clinical evidence and establish our cost-savings footprint in the emerging medical device marketplace." Procellera ® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple indications. For more information about Procellera ®, please visit www.vomaris.com. About Vomaris Innovations, Inc.Vomaris Innovations, Inc., based in Chandler, Arizona, is a leading edge regenerative medical device company specializing in bioelectrical field generating technologies for the wound care market. FDA cleared, Procellera ® is the world's first wireless, self-contained antimicrobial wound device that generates a sustained electrical microcurrent at the wound surface when activated with a conductive fluid. Procellera ® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites. Randomized clinical trials are in process looking at other possible wound healing benefits for the use of Procellera ®. For more information, visit www.vomaris.com or call 480.921.4948. SOURCE Vomaris Innovations, Inc.